Memórias do Instituto Oswaldo Cruz Fundação Oswaldo Cruz, Fiocruz ISSN: 1678-8060 EISSN: 1678-8060 Vol. 100, Num. s1, 2005, pp. 113-120

Mem Inst Oswaldo Cruz, Rio de Janeiro, Vol.100, Suppl. 1, March, 2005, pp. 113-120

Mechanisms of leukocyte lipid body formation and function in inflammation

Patrícia T Bozza⁺, Christianne Bandeira-Melo

Laboratório de Imunofarmacologia, Departamento de Fisiologia e Farmacodinâmica, Instituto Oswaldo Cruz-Fiocruz,
Av. Brasil 4365, 21040-900 Rio de Janeiro, RJ, Brasil
Financial support: Howard Hughes Medical Institute (to PTB), Fogarty International Center-NIH, Pronex-MCT, CNPq, Profix, Faperj
⁺Corresponding author. E-mail: pbozza@ioc.fiocruz.br

Received 8 November 2004
Accepted 30 December 2004

Code number: oc05037

An area of increasingly interest for the understanding of cell signaling are the spatio-temporal aspects of the different enzymes involved in lipid mediator generation (eicosanoid-forming enzymes, phospholipases and their regulatory kinases and phosphatases) and pools of lipid precursors. The compartmentalization of signaling components within discrete and dynamic sites in the cell is critical for specificity and efficiency of enzymatic reactions of phosphorilation, enzyme activation and function. We hypothesized that lipid bodies - inducible non-membrane bound cytoplasmic lipid domains - function as specialized intracellular sites of compartmentalization of signaling with major roles in lipid mediator formation within leukocytes engaged in inflammatory process. Over the past years substantial progresses have been made demonstrating that all enzymes involved in eicosanoid synthesis localize at lipid bodies and lipid bodies are distinct sites for eicosanoid generation. Here we will review our current knowledge on the mechanisms of formation and functions of lipid bodies pertinent to inflammation.

Key words: inflammation - lipid bodies - eicosanoids

The cells of both innate and adaptive immune response express a great variety of receptors that transduce and integrate an enormous amount of information enabling the cells to mount effective immune responses. Over the past several years major advances have been made to elucidate the biochemical and molecular details of cell activation and depicting signaling cascades that leads to inflammatory mediator production. However the temporal and spatial organization of signaling and its impact on cell function is less clear. Recent evidence indicates that immune receptors and components of their signaling cascade are spatially organized within the cell and this spatial organization plays a key role in the regulation and amplification of cell signaling.

Many studies have delineated roles for lipid domains including plasma membrane-associated domains - lipid rafts and caveolae and intracellular lipid-rich domains - named lipid bodies -, in cellular signaling. The functions of rafts and caveolae in cell signaling have been recently reviewed elsewhere (Anderson & Jacobson 2002, Dykstra et al. 2003, Pike 2003, van Deurs et al. 2003, Helms & Zurzolo 2004). Cytoplasmic lipid bodies are osmiophilic organelles present in virtually all mammalian cells, which are surrounded by a monolayer of phospholipids with a unique fatty acid composition, have a neutral lipid-rich core, and present variable protein composition (Murphy 2001, van Meer 2001, Tauchi-Sato et al. 2002). Members of the PAT family of proteins [perilipin, adipose-differentiation related protein (ADRP) and TIP 47], in particular ADRP, have been ubiquitously associated to lipid bodies in different cell types, including leukocytes, and although their function are not fully understood, they seem to act as structural proteins surrounding lipid bodies serving as nucleation center for lipid assembling and/or acting as an anchor for subcellular locations within the cell (Heid et al. 1998, Nakamura & Fujimoto 2003, Brasaemle et al. 2004). It is hypothesized that lipid body lipidic and proteic composition varies according to the cell type and stimulatory conditions, with impacts to their function in the cell. Here we review the evidence that leukocyte lipid body formation and compartmentalization of enzymes within lipid bodies is a highly regulated cellular event and that lipid bodies play a key role in the heightened capacity of leukocytes to generate eicosanoids in inflammatory conditions.

MECHANISMS OF LEUKOCYTE LIPID BODY FORMATION

Lipid bodies, although small in number, are normal constituent of leukocytes, including eosinophils, neutrophils, and monocyte/macrophages. Although lipid bodies, lipid-enriched organelles often overlooked if their defining lipid content is lost during cell staining, have long been noted to be prominent in many cell types associated with inflammation, the genesis and function of these organelles are still not completely defined. Indeed, most routinely used hematological staining protocols including May-Grünwald-Giemsa staining cause dissolution of lipid bodies (Fig. 1b, d), which precludes their recognition in stimulated leukocytes. However, with appropriate lipid fixation and staining, increased lipid body numbers have been observed in activated leukocytes as after LPS administration in vivo (Fig. 1c), compared with the control (Fig. 1a). Lipid bodies were shown to characteristically increase both in size and number in vivo in cells associated with human inflammatory diseases; including in blood eosinophils from patients with hypereosinophilic syndrome (HES) and in tissue eosinophils in biopsies from Crohn's disease (Solley et al. 1976, Beil et al. 1995, Bozza et al. 1998), in synovial leukocytes from patients with arthritis (Weinstein 1980, Schlesinger et al. 1982, Reginato et al. 1985, Bozza et al. 1996b) and lung and blood leukocytes from septic and/or ARDS patients (Triggiani et al. 1995, Pacheco et al. 2002).

Genesis of new lipid bodies is not a manifestation of cellular injury or simply attributable to excess substrate fatty acids, on the contrary, it is a rapid, highly regulated phenomenon that is stimulus and cell specific (Fig. 2). For instance, lipid bodies can be elicited in vivo and in vitro after stimulation of cells with either lipid agonists such as, cis-unsaturated fatty acids, PAF, LPS or PKC activators (Weller et al. 1989, 1991 Bozza et al. 1996a, b, Pacheco et al. 2002) or protein stimuli such as chemokines and interleukines (Bozza et al. 1998, Bartemes et al. 1999, Bandeira-Melo et al. 2001a, 2002a).

Neutrophil lipid bodies, identical to lipid bodies in leukocytes in vivo as evidenced by light and electron microscopy (EM), can also be rapidly (within 15-60 min) elicited in vitro after stimulation with cis-unsaturated fatty acids, PAF, or PKC activators (Weller et al. 1989, 1991, Bozza et al. 1996a, b). Although incubation of leukocytes with exogenous phospholipids and fatty acids provides a source of lipids for incorporation into newly formed lipid bodies, mechanisms other than simple availability of lipid precursors seem to be involved in lipid body formation. First, specific unsaturated fatty acids, including non-esterifiable analogs, in a stereochemically-restricted manner, can elicit de novo formation of lipid bodies in human leukocytes, whereas fully saturated fatty acids are not active (Weller et al. 1989, 1991, Bozza & Weller 2001).

Moreover, PAF but not its precursor and metabolite, lyso-PAF, that shares the lipid structure of PAF but has no receptor agonistic activity (Prescott et al. 2000), have the capacity to induce lipid body formation (Bozza et al. 1996a, 1997, de Assis et al. 2003). In addition, it has been demonstrated that PAF-induced lipid body formation in leukocytes involves the regulated activation of different signaling pathways (Fig. 1). PAF stimulated lipid body is a receptor-dependent phenomenon, inhibitable by PAF receptor antagonist and pertussis toxin (Bozza et al. 1996a, 1997, 1998). PAF, acting via its G-protein-linked receptor induces lipid body formation via a downstream signaling involving, sequentially, 5-LO activation to generate 5-HETE that per se activates its G-protein-linked receptor, and protein kinase C activation (Bozza et al. 1996a). Interestingly other neutrophil agonists IL8, C5a, and LTB4 acting through G protein coupled receptors were not capable of inducing neutrophil lipid body formation (Bozza et al. 1996a).

Of special relevance to allergic inflammation, key mediators of the allergic response in addition to PAF are capable of eliciting newly formed lipid bodies within human eosinophils. IL-5 (a stimuli proteic in nature) alone or combined to GM-CSF in the absence of exogenous lipids as well as immobilized IgG lead to significant increase in lipid body numbers (Bozza et al. 1998, Bartemes et al. 1999), suggesting that receptor mediated stimuli results in intracellular lipid remodeling and lipid body formation. Moreover, chemokines acting via CCR3 receptors, including RANTES, eotaxin, eotaxin-2, and eotaxin-3, can initiate intracellular signaling in eosinophils, but not neutrophils, that also culminate in de novo formation of lipid bodies (Bandeira-Melo et al. 2001a, b). Differently from the signaling pathways described by PAF, eotaxin and RANTES activating CCR3 receptor signals through phospho-inositide 3-kinase (PI3K) and the ERK1/2 and p38 MAP kinases (Bandeira-Melo et al. 2001a).

Increased lipid body formation in neutrophils and macrophages could also be observed in experimentally induced inflammation triggered either by LPS or OxLDL (oxidized low density lipoprotein) but not by native LDL (Pacheco et al. 2002, Silva et al. 2002). LPS administration into mice induced a dose- and time-dependent increase in lipid body numbers. Moreover, LPS failed to form lipid bodies in C3H/HeJ (TLR4 mutated) mice or in cells treated with neutralizing anti-CD14, demonstrating a requisite role for LPS receptors in lipid body formation (Pacheco et al. 2002). Infection by T. cruzi also leads to increase in lipid body numbers in macrophages (Melo et al. 2003), whether this reaction would also involve pattern recognition receptors are now under investigation.

PAF and PAF-like lipids are believed to play an important role in lipid body formation induced by LPS or by oxLDL in vivo since the pretreatment with three structurally unrelated PAF receptor antagonists completely inhibited this phenomenon (Pacheco et al. 2002, Silva et al. 2002). Although PAF may act at intracellular binding sites to induce cell activation (Bazan et al. 1994), results are suggestive that PAF is acting in a paracrine/autocrine way to induce lipid body formation, since the PAF-receptor antagonist used in those studies would act preferentially at membrane receptors and confirmed by findings that LPS or oxLDL induced lipid body formation were inhibitable by treatment with extracellular PAH-acetylhidrolase (Silva et al. 2002).

It has been demonstrated that dietary fatty acids may have impacts on cellular lipid domains (Yaqoob 2003). Consumption of the long chain n-3 PUFA has been demonstrated to modify composition of lipid rafts and caveolae (Stulnig et al. 2001, Fan et al. 2003, 2004, Ma et al. 2004). We have recently demonstrated that fatty acid dietary intake may also modulate leukocyte lipid body formation. Indeed, dietary intake of extra virgin olive oil lead to inhibition of LPS-induced lipid body formation and decreased generation of MCP-1 and eico-sanoids (Leite et al. 2005).

Interestingly, the pretreatment of leukocytes with protein synthesis inhibitors acting on transcription (actinomycin D) and translation (cycloheximide) significantly, although partially, inhibited lipid body formation induced by PAF and fatty acids in vitro but not by eotaxin and RANTES, thus indicating that according to the stimulated conditions induction of lipid bodies depends on new protein synthesis and its likely that specific and transcriptionaly regulated early response genes are activated during the process of lipid body formation (Bozza et al. 1996a, b, 1997, Bandeira-Melo et al. 2001a, Pacheco et al. 2002). A role for peroxisome proliferator-activated receptors (PPARs), members of the nuclear receptor supergene family that function in ligand-activated transcription, in leukocyte lipid body formation has recently been suggested. Indeed, we observed that treatment of mouse macrophages with BRL 49653, a preferential PPARg ligand, failed to induce lipid body formation. However, BRL 49653 treatment significantly potentiated lipid body formation induced by ox-LDL or PAF-like agonists, suggesting that PPAR have a role in regulating leukocyte lipid body formation (de Assis et al. 2003). However, we anticipate that differences in PPAR expression and role in lipid body formation may vary according to the cell type and stimuli studied and further studies are needed to characterize the roles of PPAR in lipid body formation and the involvement of PPAR targeted genes in this phenomenon.

The formation of structurally distinct lipid bodies reflects mechanisms whereby proteins and lipids coalesce in a deliberate, highly regulated manner. Lipid body assembly can result from mobilization and reorganization of endogenously derived lipids as well as incorporating exogenous lipid. Thus, although lipid bodies are not conventional membrane-bound organelles, they appear to represent specialized intracellular domains whose induced formation is centrally related to activating mechanisms within the cells. Moreover, lipid body size and numbers are characteristically increased in leukocytes following activation in vitro as well as in in vivo inflammatory disorders, and can be used as a marker of leukocyte activation.

LEUKOCYTE LIPID BODY FUNCTIONS IN INFLAMMATION

Eicosanoid-forming enzyme compartmentalization - Several findings indicate a major role of lipid bodies in arachidonic acid metabolism during inflammation. First, lipid bodies are intracellular sites of arachidonate esterified within both neutral lipids (triacylglycerol and cholesterol) as well as in different phospholipid classes in cells including eosinophils, neutrophils and macrophages (Weller et al. 1989, 1991, Yu et al. 1998, Johnson et al. 1999). If lipid bodies are to have roles in eicosanoid mediator formation, then the arachidonic acid present in those lipid-rich structures must be released by phospholipases, and the free arachidonate must have access to eicosanoid-forming enzymes. Accordingly, the co-compartmentalization of cytosolic phospholipase A₂ (cPLA₂) and mitogen-activated protein (MAP) kinases, the upstream enzymes involved in AA liberation, within lipid bodies has been described (Yu et al. 1998). Immunocytochemistry from whole cell and immunoblotting of proteins from isolated lipid bodies (free of cytosol and other organelles) established that cPLA₂ as well as the MAP kinases, ERK1, ERK2, p85, and p38, were localized at lipid bodies. In addition, isolated lipid body fractions contained cPLA₂ enzymatic activity and released AA from sn-2-position of phosphatidylcholine (Yu et al. 1998).

The two major enzymes, 5-LO and COX, involved in the enzymatic conversion of AA into eicosanoids were also shown to localize within lipid bodies. By using immunocytochemistry at the light level and ultrastructural postembedding immunogold, cyclooxygenase has been reported to localize at eosinophil lipid bodies, both in naturally formed lipid bodies in eosinophils from HES patients and in PAF-induced lipid bodies (Dvorak et al. 1992, 1993, Bozza et al. 1997, 1998). Previous studies on the intracellular localization of 5-LO have shown that 5-LO localization is cell type-specific and also varies according to the activation state of the cell. 5-LO was shown to localize within the nuclear environment (nuclear membrane and euchromatin) of alveolar macrophages and basophilic leukemia cells, whereas 5-LO was found to be predominantly cytosolic in human neutrophils and resting peritoneal macrophages (Peters-Golden & Brock 2000, Bandeira-Melo & Weller 2003). In addition to the nuclear environment, we have demonstrated the compartmentalization of the key enzyme for leukotriene production, 5-LO, within human eosinophil and basophil lipid bodies (Bozza et al. 1997, 1998, Bandeira-Melo et al. 2001a). In addition, im-muno-reactivity for 5-LO was also detected in lipid bodies from enucleated human eosinophils (Bozza et al. 1997).

Human eosinophils upon stimulation preferentially produce LTC₄ as their 5-LO product. LTC₄-synthase is the terminal LT-forming enzyme and is present selectively in eosinophils, basophils, and mast cells (Bandeira-Melo et al. 2002a). Similarly to that observed for 5-LO, LTC₄-synthase was shown to co-localize within eosinophil lipid bodies (Bozza et al. 1997).

Sub-cellular localization of eicosanoid forming enzymes in leukocytes in vivo is starting to be unveiled. Li-pid bodies, in both ox-LDL- and LPS-induced models of inflammation, compartmentalize 5-LO and COX-2 enzymes within recruited leukocytes (Pacheco et al. 2002, de Assis et al. 2003). Similarly, eosinophils attracted to the site of allergic reaction showed 5-LO and COX-2 immuno-reactivity within newly formed lipid bodies. In addition, lipid bodies within leukocytes obtained from clinical inflammatory conditions including sepsis and arthritis were also demonstrated to be domains for intracellular compartmentalization of 5-LO and COX-2 (Pacheco et al. 2002, Roimicher, unpub. data).

Together these findings support a role for lipid bodies to function as specific sites for eicosanoid formation. The compartmentalization of arachidonate substrate, cPLA₂, and eicosanoid-forming enzymes provides in one locale an efficient mean to regulate arachidonate release and directly couple it with the enzymes to form eicosanoids (Table).

Involvement of lipid bodies in enhanced generation of eicosanoids by inflammatory cells - Because leukocyte lipid bodies are sites of intracellular localization of eicosanoid-forming enzymes and also stores of the eicosanoid precursor arachidonic acid, it has been hypothesized that increases in lipid body numbers in leukocytes would result in enhanced capacity of eicosanoid production by leukocytes. Indeed, stimuli known to prime leukocytes to induce eicosanoid generation, including PKC activators, arachidonate and PAF, are also active in stimulating lipid body formation. Accordingly, others and we observed a significant correlation between lipid body formation and enhanced generation of both LO- and COX-derived eicosanoids in vitro (Bozza et al. 1996a, b, 1997, 1998, Bartmenes et al. 1999) as well as in vivo (Pacheco et al. 2002, Silva et al. 2002, de Assis et al. 2003, Melo et al. 2003).

Analogously, agents that inhibited lipid body formation also resulted in inhibited priming for eicosanoid production. Indeed, lipid body formation induced by unsaturated fatty acids is inhibited by non-steroidal anti-inflammatory drugs (NSAIDs) including aspirin, indomethacin and, the non-cyclooxygenase inhibitor, sodium salicylate (Bozza et al. 1996b). Moreover, these NSAIDs block the priming response for increased prostanoid and leukotriene formation through a mechanism independent of their effects on cyclooxygenase but correlated with their capacity to inhibit lipid body formation (Bozza et al. 1996b, 2002). In addition, pretreatment of granulocytes with the protein synthesis inhibitors actinomycin D or cycloheximide inhibited not only PAF-induced lipid body formation, but also priming for LTC₄ and PGE₂ release by leukocytes, under conditions where they failed to inhibited calcium ionophore-induced LTC₄ and PGE₂ in cells not prestimulated with PAF (Bozza et al. 1996a, 1997).

In order to evaluate if lipid bodies are sites involved in enhanced eicosanoid formation independently of the nuclear-pool of eicosanoid-forming enzymes and lipids, eosinophil enucleated cytoplasts were studied. As observed with intact eosinophils, PAF-induced a dose-dependent increase in the number of lipid bodies in eosinophil cytoplasts. Likewise, PAF-induced lipid body formation in nuclei-free cytoplast strongly correlated with increased LTC₄ and PGE₂ production following submaximal stimulation with A23187 (Bozza et al. 1997).

That lipid bodies function as distinct extranuclear sites for eicosanoid formation was confirmed by the direct intracellular localization of newly formed eicosanoid. Direct assessment of intracellular sites for eicosanoid has been elusive, as those mediators are newly formed, non-storable and rapidly released upon cell stimulation. Recently, a new strategy to cross-link newly formed LTC₄ at its sites of synthesis within in vitro stimulated eosinophils was described, enabling the immunofluorescent localization of newly formed LTC₄ at its intracellular formation locale (Bandeira-Melo et al. 2001a, 2002b). Lipid bodies were the predominant sites of LTC₄ synthesis in chemokine-stimulated human eosinophils. Therefore, CC chemokines elicit the formation of lipid body domains and promote LTC₄ formation at these specific sites. Lipid bodies are also newly recognized sites of synthesis eico-sanoids that act as intracrine mediators regulating the release of a major cytokine, IL-4, stored within eosinophil granules (Bandeira-Melo & Weller 2005, in this issue).

Collectively these findings indicate that lipid bodies are cytoplasmic, nuclei independent, sites for eicosanoid-forming enzyme localization, and eicosanoid production. Taken together with the evidences indicating the nucleus environment as important pools for eicosanoid metabolism (Serhan et al. 1996, Peters-Golden & Brock 2000, Bandeira-Melo & Weller 2003), raises intriguing possibilities that different sites for eicosanoid production might exist in a cell leading to the production of eicosanoids with intracrine function on regulation of transcription or regulating degranulation and for external release as para-crine inflammatory mediators.

Putative lipid body functions based on protein compartmentalization - Recent studies focusing on the protein profile of lipid bodies in different cell types have revealed how broad lipid body functions can be. Among a growing list of proteins found within lipid bodies, it is known that they compartmentalize fatty acid metabolic enzymes, caveolin, kinases, small GTPases and cytokines, and therefore lipid bodies may regulate lipid metabolism, membrane trafficking, intracellular signaling and cell to cell communication.

Although not yet characterized in leukocytes, lipid bodies from different cell types are sites of localization of lipid metabolic enzymes, including key enzymes involved in cholesterol metabolism (squalene epoxidase, 17-b-hydroxysteroid dehydrogenase, lanosterol synthase) and key enzymes of fatty acid synthesis (acetyl-coenzyme A carboxilase, NADH cytochrome b5 reductase), suggesting that both anabolic and catabolic steps in lipid metabolism may take place at lipid bodies (Brasaemle et al. 2004, Fujimoto et al. 2004, Liu et al. 2004, Umlauf et al. 2004). Proteins potentially associated with lipid trafficking including the cholesterol-binding protein caveolin and stomatin may be targeted to lipid bodies according to stimulatory conditions (Fujimoto et al. 2001, Ostermeyer et al. 2001, Pol et al. 2001, 2004, Umlauf et al. 2004). Moreover, the finding that cytosolic phospholipase A₂ (cPLA₂) and mitogen-activated proteins (MAP) kinases (also known as extracellular signal-regulated kinases [ERKs]), protein kinase C (PKC) and phosphatidylinositide 3-kinase (PI3K) - key enzymes implicated in intracellular lipid signaling of diverse cellular responses - are present at leukocyte lipid bodies suggests that regulatory signal transduction responses occur at lipid body domains (Yu et al. 1998, 2000, Chen et al. 2002) (Table).

Of interest to the functions lipid bodies may have in inflammation, it has been demonstrated that cytokines, chemokines, and growth factors can be localized intracellularly in lipid bodies formed in activated leukocytes (Table). TNF-α was detected by an immunogold ultrastructural morphometric approach within cytoplasmic lipid bodies of several cell types, including fibroblasts, eosinophils, macrophages, mast cells, colonic epithelial cells and neutrophils in colonic Crohn's disease biopsies (Beil et al. 1995). TNF-α, were also shown to co-localize within leukocyte lipid bodies formed after LPS stimulation in vivo and within lipid bodies from peripheral blood neutrophils and monocytes from septic patients (Pacheco et al. 2002). Cytoplasmic lipid bodies of isolated human lung mast cells contain the basic fibroblast growth factor (bFGF), also found within mast cell secretory granules (Dvorak et al. 2001). Moreover, lipid bodies within human eosinophils are sites of localization of preformed RANTES and IL-16 (Lim et al. 1996), which are important eosinophil and lymphocyte activating agonists, and thus lipid bodies may have functions in allergic inflammation beside its role in LTC₄ generation. Whether and how cytokines are released from lipid bodies, and whether cytokines have signaling functions within lipid bodies are questions that remain to be addressed.

CONCLUDING REMARKS

This review presents leukocyte lipid bodies as specialized, inducible intracellular domains that function as signaling platforms in inflammatory mediator production in the sense that the compartmentalization of substrate and key enzymes within intracellular lipid bodies have direct impact on the capacity of activated leukocytes to generate increased amounts of eicosanoids. Moreover, lipid bodies constitute sites of intracellular cytokine localization and may have functions beyond arachidonic acid metabolism. The emerging role of lipid bodies as inflammatory organelles raises lipid body status to critical regulators of different inflammatory diseases and key markers of leukocyte activation.

REFERENCES

• Anderson RG, Jacobson K 2002. A role for lipid shells in targeting proteins to caveolae, rafts, and other lipid domains. Science 296: 1821-1825.
• Bandeira-Melo C, Weller PF 2003. Eosinophils and cysteinyl leukotrienes. Prostaglandins Leukot Essent Fatty Acids 69: 135-143.
• Bandeira-Melo C, Weller PF 2005. Mechanisms of eosinophil cytokine release. Mem Inst Oswaldo Cruz 100 (Suppl I.): 73-81.
• Bandeira-Melo C, Bozza PT, Weller PF 2002a. The cellular biology of eosinophil eicosanoid formation and function. J Allergy Clin Immunol 109: 393-400.
• Bandeira-Melo C, Phoofolo M, Weller PF 2001a. Extranuclear lipid bodies, elicited by CCR3-mediated signaling pathways, are the sites of chemokine-enhanced leukotriene C4 production in eosinophils and basophils. J Biol Chem 276: 22779-22787.
• Bandeira-Melo C, Sugiyama K, Woods LJ, Weller PF 2001b. Cutting edge: eotaxin elicits rapid vesicular transport-mediated release of preformed IL-4 from human eosinophils. J Immunol 166: 4813-4817.
• Bandeira-Melo C, Woods LJ, Phoofolo M, Weller PF 2002b. Intracrine cysteinyl leukotriene receptor-mediated signaling of eosinophil vesicular transport-mediated interleukin-4 secretion. J Exp Med 196: 841-850.
• Bartemes KR, McKinney S, Gleich GJ, Kita H 1999. Endogenous platelet-activating factor is critically involved in effector functions of eosinophils stimulated with IL-5 or IgG. J Immunol 162: 2982-2989.
• Bazan NG, Fletcher BS, Herschman HR, Mukherjee PK 1994. Platelet-activating factor and retinoic acid synergistically activate the inducible prostaglandin synthase gene. Proc Natl Acad Sci USA 91: 5252-5256.
• Beil WJ, Weller PF, Peppercorn MA, Galli SJ, Dvorak AM 1995. Ultrastructural immunogold localization of subcellular sites of TNF-alpha in colonic Crohn's disease. J Leukoc Biol 58: 284-298.
• Bozza PT, Weller PF 2001. Arachidonyl trifluoromethyl ketone induces lipid body formation in leukocytes. Prostaglandins Leukot Essent Fatty Acids 64: 227-230.
• Bozza PT, Pacheco P, Yu W, Weller PF 2002. NS-398: cyclo-oxygenase-2 independent inhibition of leukocyte priming for lipid body formation and enhanced leukotriene generation. Prostaglandins Leukot Essent Fatty Acids 67: 237-244.
• Bozza PT, Payne JL, Goulet JL, Weller PF 1996a. Mechanisms of platelet-activating factor-induced lipid body formation: requisite roles for 5-lipoxygenase and de novo protein synthesis in the compartmentalization of neutrophil lipids. J Exp Med 183: 1515-1525.
• Bozza PT, Payne JL, Morham SG, Langenbach R, Smithies O, Weller PF 1996b. Leukocyte lipid body formation and eicosanoid generation: cyclooxygenase-independent inhibition by aspirin. Proc Natl Acad Sci USA 93: 11091-11096.
• Bozza PT, Yu W, Cassara J, Weller PF 1998. Pathways for eosinophil lipid body induction: differing signal transduction in cells from normal and hypereosinophilic subjects. J Leukoc Biol 64: 563-569.
• Bozza PT, Yu W, Penrose JF, Morgan ES, Dvorak AM, Weller PF 1997. Eosinophil lipid bodies: specific, inducible intracellular sites for enhanced eicosanoid formation. J Exp Med 186: 909-920.
• Brasaemle DL, Dolios G, Shapiro L, Wang R 2004. Proteomic analysis of proteins associated with lipid droplets of basal and lipolytically stimulated 3T3-L1 adipocytes. J Biol Chem 279: 46835-46842.
• Chen JS, Greenberg AS, Wang SM 2002. Oleic acid-induced PKC isozyme translocation in RAW 264.7 macrophages. J Cell Biochem 86: 784-791.
• de Assis EF, Silva AR, Caiado LF, Marathe GK, Zimmerman GA, Prescott SM, McIntyre TM, Bozza PT, de Castro-Faria-Neto HC 2003. Synergism between platelet-activating factor-like phospholipids and peroxisome proliferator-activated receptor gamma agonists generated during low density lipoprotein oxidation that induces lipid body formation in leukocytes. J Immunol 171: 2090-2098.
• Dvorak AM, Morgan ES, Weller PF 2001. Ultrastructural immunolocalization of basic fibroblast growth factor to lipid bodies and secretory granules in human mast cells. Histochem J 33: 397-402.
• Dvorak AM, Morgan E, Schleimer RP, Ryeom SW, Lichtenstein LM, Weller PF 1992. Ultrastructural immunogold localization of prostaglandin endoperoxide synthase (cyclooxyge-nase) to non-membrane-bound cytoplasmic lipid bodies in human lung mast cells, alveolar macrophages, type II pneumocytes, and neutrophils. J Histochem Cytochem 40: 759-769.
• Dvorak AM, Weller PF, Harvey VS, Morgan ES, Dvorak HF 1993. Ultrastructural localization of prostaglandin endoperoxide synthase (cyclooxygenase) to isolated, purified fractions of guinea pig peritoneal macrophage and line 10 hepatocarcinoma cell lipid bodies. Int Arch Allergy Immunol 101: 136-142.
• Dykstra M, Cherukuri A, Sohn HW, Tzeng SJ, Pierce SK 2003. Location is everything: lipid rafts and immune cell signaling. Annu Rev Immunol 21: 457-481.
• Fan YY, Ly LH, Barhoumi R, McMurray DN, Chapkin RS 2004. Dietary docosahexaenoic acid suppresses T cell protein kinase C theta lipid raft recruitment and IL-2 production. J Immunol 173: 6151-6160.
• Fan YY, McMurray DN, Ly LH, Chapkin RS 2003. Dietary (n-3) polyunsaturated fatty acids remodel mouse T-cell lipid rafts. J Nutr 133: 1913-1920.
• Fujimoto T, Kogo H, Ishiguro K, Tauchi K, Nomura R 2001. Caveolin-2 is targeted to lipid droplets, a new "membrane domain" in the cell. J Cell Biol 152: 1079-1085.
• Fujimoto Y, Itabe H, Sakai J, Makita M, Noda J, Mori M, Higashi Y, Kojima S, Takano T 2004. Identification of major proteins in the lipid droplet-enriched fraction isolated from the human hepatocyte cell line HuH7. Biochim Biophys Acta 1644: 47-59.
• Heid HW, Moll R, Schwetlick I, Rackwitz HR, Keenan TW 1998. Adipophilin is a specific marker of lipid accumulation in diverse cell types and diseases. Cell Tissue Res 294: 309-321.
• Helms JB, Zurzolo C 2004. Lipids as targeting signals: lipid rafts and intracellular trafficking. Traffic 5: 247-254.
• Johnson MM, Vaughn B, Triggiani M, Swan DD, Fonteh AN, Chilton FH 1999. Role of arachidonyl triglycerides within lipid bodies in eicosanoid formation by human polymorphonuclear cells. Am J Respir Cell Mol Biol 21: 253-258.
• Leite MS, Pacheco P, Gomes RN, Guedes AT, Castro-Faria-Neto HC, Bozza PT, Koatz VLG 2005. Mechanisms of increased survival after lipopolysaccharide-induced endotoxic shock in mice consuming olive oil-enriched diet. Shock 23: 173-178.
• Lim KG, Wan HC, Bozza PT, Resnick MB, Wong DT, Cruikshank WW, Kornfeld H, Center DM, Weller PF 1996. Human eosinophils elaborate the lymphocyte che-moattractants. IL-16 (lymphocyte chemoattractant factor) and RANTES. J Immunol 156: 2566-2570.
• Liu P, Ying Y, Zhao Y, Mundy DI, Zhu M, Anderson RG 2004. Chinese hamster ovary K2 cell lipid droplets appear to be metabolic organelles involved in membrane traffic. J Biol Chem 279: 3787-3792.
• Ma DW, Seo J, Davidson LA, Callaway ES, Fan YY, Lupton JR, Chapkin RS 2004. n-3 PUFA alter caveolae lipid composition and resident protein localization in mouse colon. Faseb J 18: 1040-1042.
• Melo RC, D'Avila H, Fabrino DL, Almeida PE, Bozza PT 2003. Macrophage lipid body induction by Chagas disease in vivo: putative intracellular domains for eicosanoid formation during infection. Tissue Cell 35: 59-67.
• Murphy DJ 2001. The biogenesis and functions of lipid bodies in animals, plants and microorganisms. Prog Lipid Res 40: 325-438.
• Nakamura N, Fujimoto T 2003. Adipose differentiation-related protein has two independent domains for targeting to lipid droplets. Biochem Biophys Res Commun 306: 333-338.
• Ostermeyer AG, Paci JM, Zeng Y, Lublin DM, Munro S, Brown DA 2001. Accumulation of caveolin in the endoplasmic reticulum redirects the protein to lipid storage droplets. J Cell Biol 152: 1071-1078.
• Pacheco P, Bozza FA, Gomes RN, Bozza M, Weller PF, Castro-Faria-Neto HC, Bozza PT 2002. Lipopolysaccharide-induced leukocyte lipid body formation in vivo: innate immunity elicited intracellular Loci involved in eicosanoid metabolism. J Immunol 169: 6498-6506.
• Peters-Golden M, Brock TG 2000. Intracellular compartmentalization of leukotriene biosynthesis. Am J Respir Crit Care Med 161: S36-40.
• Pike LJ 2003. Lipid rafts: bringing order to chaos. J Lipid Res 44: 655-667.
• Pol A, Luetterforst R, Lindsay M, Heino S, Ikonen E, Parton RG 2001. A caveolin dominant negative mutant associates with lipid bodies and induces intracellular cholesterol imbalance. J Cell Biol 152: 1057-1070.
• Pol A, Martin S, Fernandez MA, Ferguson C, Carozzi A, Luetterforst R, Enrich C, Parton RG 2004. Dynamic and regulated association of caveolin with lipid bodies: modulation of lipid body motility and function by a dominant negative mutant. Mol Biol Cell 15: 99-110.
• Prescott SM, Zimmerman GA, Stafforini DM, McIntyre TM 2000. Platelet-activating factor and related lipid mediators. Annu Rev Biochem 69: 419-445.
• Reginato AJ, Schumacher HR, Allan DA, Rabinowitz JL 1985. Acute monoarthritis associated with lipid liquid crystals. Ann Rheum Dis 44: 537-543.
• Schlesinger PA, Stillman MT, Peterson L 1982. Polyarthritis with birefringent lipid within synovial fluid macrophages: case report and ultrastructural study. Arthritis Rheum 25: 1365-1368.
• Serhan CN, Haeggstrom JZ, Leslie CC 1996. Lipid mediator networks in cell signaling: update and impact of cytokines. Faseb J 10: 1147-1158.
• Silva AR, de Assis EF, Caiado LF, Marathe GK, Bozza MT, McIntyre TM, Zimmerman GA, Prescott SM, Bozza PT, Castro-Faria-Neto HC 2002. Monocyte chemoattractant protein-1 and 5-lipoxygenase products recruit leukocytes in response to platelet-activating factor-like lipids in oxidized low-density lipoprotein. J Immunol 168: 4112-4120.
• Solley GO, Maldonado JE, Gleich GJ, Giuliani ER, Hoagland HC, Pierre RV, Brown Jr AL 1976. Endomyocardiopathy with eosinophilia. Mayo Clin Proc 51: 697-708.
• Stulnig TM, Huber J, Leitinger N, Imre EM, Angelisova P, Nowotny P, Waldhausl W 2001. Polyunsaturated eico-sapentaenoic acid displaces proteins from membrane rafts by altering raft lipid composition. J Biol Chem 276: 37335-37340.
• Tauchi-Sato K, Ozeki S, Houjou T, Taguchi R, Fujimoto T 2002. The surface of lipid droplets is a phospholipid monolayer with a unique Fatty Acid composition. J Biol Chem 277: 44507-44512.
• Triggiani M, Oriente A, Seeds MC, Bass DA, Marone G, Chilton FH 1995. Migration of human inflammatory cells into the lung results in the remodeling of arachidonic acid into a triglyceride pool. J Exp Med 182: 1181-1190.
• Umlauf E, Csaszar E, Moertelmaier M, Schuetz GJ, Parton RG, Prohaska R 2004. Association of stomatin with lipid bodies. J Biol Chem 279: 23699-23709.
• van Deurs B, Roepstorff K, Hommelgaard AM, Sandvig K 2003. Caveolae: anchored, multifunctional platforms in the lipid ocean. Trends Cell Biol 13: 92-100.
• van Meer G 2001. Caveolin, cholesterol, and lipid droplets? J Cell Biol 152: F29-34.
• Weinstein J 1980. Synovial fluid leukocytosis associated with intracellular lipid inclusions. Arch Intern Med 140: 560-561.
• Weller PF, Ackerman SJ, Nicholson-Weller A, Dvorak AM 1989. Cytoplasmic lipid bodies of human neutrophilic leukocytes. Am J Pathol 135: 947-959.
• Weller PF, Ryeom SW, Picard ST, Ackerman SJ, Dvorak AM 1991. Cytoplasmic lipid bodies of neutrophils: formation induced by cis-unsaturated fatty acids and mediated by protein kinase C. J Cell Biol 113: 137-146.
• Yaqoob P 2003. Fatty acids as gatekeepers of immune cell regulation. Trends Immunol 24: 639-645.
• Yu W, Cassara J, Weller PF 2000. Phosphatidylinositide 3-kinase localizes to cytoplasmic lipid bodies in human polymorphonuclear leukocytes and other myeloid-derived cells. Blood 95: 1078-1085.
• Yu W, Bozza PT, Tzizik DM, Gray JP, Cassara J, Dvorak AM, Weller PF 1998. Co-compartmentalization of MAP kinases and cytosolic phospholipase A2 at cytoplasmic ara-chidonate-rich lipid bodies. Am J Pathol 152: 759-769.

Copyright 2005 Instituto Oswaldo Cruz - Fiocruz

The following images related to this document are available:

Photo images